You searched for "ESCRS"
21st Century retinal laser treatment in the anti-VEGF era
In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...
Adjuvant intravitreal dexamethasone implant for persistent CME
In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...
Intravitreal aflibercept for retinal angiomatous proliferation (RAP)
In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...
Sickle cell maculopathy
This paper reports the result of a prospective study to analyse the prevalence of sickle cell maculopathy (SCM) and its associations with age, sex, genotype, proliferative sickle cell retinopathy (PSR) stage, and the impact on visual acuity (VA). This study...
IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...
Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...New Moorfields stem cell treatment improves vision for untreatable condition
A new breakthrough stem cell treatment for ARK (aniridia-related keratopathy) has seen patients’ vision improve for this previously untreatable rare genetic eye condition in a first-in-human clinical trial at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, published in...Social networking
The use of social networking is now very common in both home and work environments. The field is expanding continually and we have had some requests for a roundup of common platforms. What is social networking and social media? As...Using OneNote in teams
Much like Outlook, Word, PowerPoint and Excel, OneNote is part of Microsoft Office. For this reason it is likely that you will have access to it in your work environment. Used in isolation it is an easy to use and...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
MISS vs. fornix approach
The objectives of this study were to compare minimally invasive strabismus surgery (MISS) with the fornix approach in paediatric horizontal strabismus surgery (<12 years) and to evaluate early postoperative inflammation, visual acuity and operating time after a four-year training period...
